Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | FKBP1A | P62942 | 6/20 | 0.47 |
| ▸ | STAT6 | P42226 | 1/20 | 0.47 |
| ▸ | KLK7 | P49862 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13086597 | 1.00 | MEN1 (0.48) | MEN1NPC1RAB9AKMT2AFKBP1A | |
| SCHEMBL6012084 | 1.00 | MEN1 (0.48) | MEN1NPC1RAB9AKMT2AFKBP1A | |
| SCHEMBL13086595 | 0.99 | MEN1 (0.49) | MEN1NPC1RAB9AKMT2AFKBP1A | |
| SCHEMBL13086758 | 0.95 | MEN1 (0.50) | MEN1NPC1RAB9AKMT2AFKBP1A | |
| SCHEMBL3046705 | 0.91 | KLK7 (0.49) | MEN1NPC1RAB9AKMT2AFKBP1A | |
| SCHEMBL13086596 | 0.91 | KLK7 (0.49) | MEN1NPC1RAB9AKMT2AFKBP1A | |
| SCHEMBL2689602 | 0.91 | KLK7 (0.49) | MEN1NPC1RAB9AKMT2AFKBP1A | |
| SCHEMBL20056683 | 0.85 | KLK7 (0.46) | MEN1NPC1RAB9AKMT2AFKBP1A | |
| SCHEMBL8188560 | 0.85 | FKBP1A (0.52) | MEN1NPC1RAB9AKMT2AFKBP1A | |
| SCHEMBL8918708 | 0.85 | ACE2 (0.44) | STAT6KLK7OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261914-A1 | IAP BINDING COMPOUNDS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100261914-A1 | IAP BINDING COMPOUNDS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2010-10-14 | — | — | US | disclosed |
| US-7718600-B2 | IAP binding compounds | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2010-05-18 | — | — | US | disclosed |
| US-7718600-B2 | IAP binding compounds | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2010-05-18 | — | — | US | disclosed |
| US-20070032437-A1 | that bind cellular inhibitor of apoptosis proteins; drug design and development for diagnosis, prevention and treatment of cell proliferative disease; anticarcinogenic agents | THE TRUSTEES OF PRINCETON UNIVERSITY | 2007-02-08 | — | — | US | disclosed |
| US-20070032437-A1 | that bind cellular inhibitor of apoptosis proteins; drug design and development for diagnosis, prevention and treatment of cell proliferative disease; anticarcinogenic agents | THE TRUSTEES OF PRINCETON UNIVERSITY | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032437-A1 | that bind cellular inhibitor of apoptosis proteins; drug design and development for diagnosis, prevention and treatment of cell proliferative disease; anticarcinogenic agents | BIRC3, API5, BID | MEN1 655/4885NPC1 4365/4885RAB9A 4645/4885 |
| US-20100261914-A1 | IAP BINDING COMPOUNDS | BIRC3, BIRC5, BIRC2 | MEN1 1328/4885NPC1 3890/4885RAB9A 3827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.